Carterra Launches Industrys First 48-channel HT-SPR Platform for Advanced Label-free Biomolecular Screening and Characterization
Vega instrument combines ultra-high-throughput, data quality, and assay flexibility for both traditional…
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis
Campaign debuted during Super Bowl LX and introduced www.NextInMS.com, a new platform…
R1 Appoints Andy Brailo as Chief Commercial Officer
February 06, 2026 11:00 ET | Source: R1 RCM Holdco Inc. CHICAGO,…
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering
February 06, 2026 09:25 ET | Source: Ernexa Therapeutics Inc. CAMBRIDGE, Mass.,…
Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2026 16:01 ET | Source: Ocular Therapeutix, Inc. BEDFORD, Mass.,…
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2026 16:01 ET | Source: NewAmsterdam Pharma N.V. NAARDEN, The…
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
New facility will enable end‑to‑end discovery across key disease areas and technology…
Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met…
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
February 06, 2026 17:17 ET | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS,…
